Madrigal Pharmaceuticals Reports Q2 2026 Financial Results

What Happened Madrigal Pharmaceuticals, Inc. (MDGL) filed a Form 8-K on July 30, 2026 to announce the company's financial results for the quarter ended June 30, 2026. The company furnished a press release dated July 30, 2026 as Exhibit 99.1 to the 8-K. The filing notes the furnished press release is not deemed “filed” for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Filing: Current Report on Form 8-K, Item 2.02 (Results of Operations and Financial Condition), filed July 30, 2026.
• Period covered: Quarter ended June 30, 2026.
• Disclosure format: Press release furnished as Exhibit 99.1 (dated July 30, 2026).
• Signed on behalf of the company by Mardi Dier, Executive Vice President and Chief Financial Officer.

Why It Matters This 8-K informs investors that Madrigal has publicly released its quarterly operating and financial results; investors should review the attached press release (Exhibit 99.1) for the detailed metrics (revenue, net income/loss, cash position, and guidance if provided). Because the release is furnished rather than formally “filed,” the company limits certain legal liabilities, but the press release remains the primary source for the quarter’s financial performance.